Special items: Ovarian Cancer and Us blog best viewed in Firefox

▼
Showing posts with label recurrent. Show all posts
Showing posts with label recurrent. Show all posts
Saturday, January 21, 2012

open access: Review - 2010 Targeted Therapies in Epithelial Ovarian Cancer

›
Review Targeted Therapies in Epithelial Ovarian Cancer Download PDF Full-Text Abstract : Molecularly targeted therapy is ...
Friday, October 01, 2010

Medscape: No Benefit for Early Tx of Ovarian Cancer Relapse

›
Note : article discusses the concerns/issues/study etc
Sunday, August 15, 2010

Chemotherapy Options in the Management of Platinum-Sensitive Recurrent Ovarian Cancer

›
Note: registration required to view (free) SPECIAL EDITION / EDUCATIONAL REVIEWS ...
Tuesday, July 06, 2010

Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer

›
CONCLUSIONS.: Our study suggests that chemotherapy may be withheld for primary therapy and utilized only for recurrence.
Tuesday, May 25, 2010

Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

›
Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer...
Saturday, May 22, 2010

AJR Am J Roentgenol. 2010 Role of PET/CT in Ovarian Cancer

›
Abstract OBJECTIVE: The purpose of this article is to review the role of FDG PET/CT in ovarian cancer, which is the leading cause of deat...
Tuesday, April 13, 2010

Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab? (Avastin)

›
Monday, April 05, 2010

HE4: a new potential early biomarker for the recurrent ovarian cancer

›
"The follow-up study showed an increase of HE4 5-8 months before CA125 increment in five of the eight patients, this early expressio...
Saturday, April 03, 2010

Surveillance for the detection of recurrent ovarian cancer: Survival impact or lead-time bias?

›
Objective To compare the survival impact of diagnosing recurrent disease by routine surveillance testing versus clinical symptomatolo...
5 comments:

Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: An updated series

›
Abstract   Objective Surgical cytoreduction is an integral therapeutic modality for patients with epithelial ovarian (EOC), fallopian tube...
Friday, January 22, 2010

Maintenance immunotherapy in recurrent ovarian cancer: Long term follow-up of a phase II study

›
"Therapy consisted of low-dose subcutaneous IL-2 and oral RA, administered on intermittent schedules for up to 5 years."